Recorded Presentations from the NCCN 2025 Annual Congress: Hematologic Malignancies™

This congress focuses on updates to the NCCN Guidelines®, new and emerging therapeutic agents, and practical management strategies to ensure optimal patient outcomes.

Archived NCCN Tumor Boards: Optimizing Treatment of Chronic Phase Chronic Myeloid Leukemia
In the majority of patients with chronic myeloid leukemia (CML) responding to treatment, tyrosine kinase inhibitor (TKI) therapy has to be continued indefinitely, as long as patients are receiving clinical benefit. Adherence to TKI therapy is critical to achieving optimal responses, and the high-cost of TKIs can limit their long-term use and could potentially be a barrier to adherence to therapy.
NCCN Tumor Boards: Optimizing Treatment of Chronic Phase Chronic Myeloid Leukemia
In the majority of patients with chronic myeloid leukemia (CML) responding to treatment, tyrosine kinase inhibitor (TKI) therapy has to be continued indefinitely, as long as patients are receiving clinical benefit. Adherence to TKI therapy is critical to achieving optimal responses, and the high-cost of TKIs can limit their long-term use and could potentially be a barrier to adherence to therapy.
Chronic Myeloid Leukemia/Myelofibrosis: TKI Therapy and Toxicity Management
There is a continuing need to educate clinicians about the differences in toxicity profiles between TKIs and the various strategies that are being evaluated in clinical trials to mitigate the risk of adverse events associated with TKI therapy for CML and MPN.
Management of Chronic Phase Chronic Myeloid Leukemia with Resistance to Multiple TKIs
In the majority of patients responding to TKI therapy, chronic myeloid leukemia (CML) is now managed like a chronic disease. However, it poses significant challenges to the clinicians in terms of selection of alternate TKI therapy in patients with inadequate initial response to initial TKI therapy. Informing clinicians about the recent FDA approvals would assist in the incorporation of new treatment options into their routine clinical practice to improve patient outcomes.
Familial/Genetic Leukemia Syndromes: Impact on Patient Care
Clinicians need education regarding which patients with leukemia are candidates for genetic counseling and testing and how the management of patients with known germline mutations is affected. This knowledge will help clinicians provide these patients with optimal care.
Debate – Response Milestones that Matter in Chronic Myeloid Leukemia: MMR vs. CCyR
In view of the ongoing evolution of treatment goals, response milestones must be interpreted within the clinical context, and joint decision-making between patient and provider is important for treatment decisions, especially in ambiguous clinical situations. Expert-led education is needed to assist clinicians with the effective implementation of these strategies into their routine clinical practice.
NCCN Guidelines® Updates: Discontinuing TKI Therapy in the Treatment of Chronic Myeloid Leukemia

Data from recent clinical studies indicate that discontinuation of TKI therapy (with close monitoring) may be feasible in carefully selected patients with chronic phase CML (CP-CML), prompting the introduction of a new concept known as treatment-free remission (TFR).

Optimizing TKI Therapy for Chronic Phase CML: Sequencing of TKI Therapy and Treatment-free Remission

The availability of multiple tyrosine kinase inhibitors (TKIs) for the treatment of newly diagnosed chronic phase chronic myeloid leukemia (CML) poses significant challenges to the clinicians in terms of selection of initial TKI therapy and sequencing TKI therapy in patients with intolerance to t

Management of Chronic Myeloid Leukemia During Pregnancy

This information was originally presented at the NCCN 23rd Annual Conference: Improving the Quality, Effectiveness, and Efficiency of Cancer Care held in Orlando, Florida, from March 22 - 24, 2018.

Pages

Subscribe to RSS - Chronic Myelogenous Leukemia